Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics
GET POWR RATINGS... FREE!
FENC Stock Price Chart Interactive Chart >
FENC Price/Volume Stats
| Current price | $9.61 | 52-week high | $9.89 |
| Prev. close | $9.51 | 52-week low | $3.82 |
| Day low | $9.12 | Volume | 70,600 |
| Day high | $9.89 | Avg. volume | 73,599 |
| 50-day MA | $8.19 | Dividend yield | N/A |
| 200-day MA | $6.57 | Market Cap | 252.15M |
Fennec Pharmaceuticals Inc. (FENC) Company Bio
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.
Latest FENC News From Around the Web
Below are the latest news stories about FENNEC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FENC as an investment opportunity.
Maxim Group Keeps Their Buy Rating on Fennec Pharmaceuticals (FENC)In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Fennec Pharmaceuticals (FENC - Research Report), with a price target of $15.00. The company's shares opened today at $7.93.According to TipRanks, McCarthy is an analyst with an average return of -38.1% and a 14.47% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.Fennec Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $15.75.See the top stocks recommended by analysts >>The company has a one-year high of $10.05 and a one-year low of $3.82. |
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ~ Initiated U.S. Commercial Launch of PEDMARK® in October 2022 ~ ~ Closed $25 Million in Funding from Petrichor to Support the U.S. Commercialization of PEDMARK®, With the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ RESEARCH TRIANGLE PARK, N.C., Nov. 11 |
Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Are Analysts Optimistic?Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is possibly approaching a major achievement in its business, so we would... |
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS™ Program Offers Comprehensive Patient Services, Including Access to Care Coordinators, Financial and Prescription Drug Support ~ RESEARCH TRIANGLE PARK, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the U.S. commercial launch an |
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20, 2022 ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today |
FENC Price Returns
| 1-mo | 14.13% |
| 3-mo | 37.29% |
| 6-mo | 64.84% |
| 1-year | 101.05% |
| 3-year | 206.98% |
| 5-year | 98.35% |
| YTD | 118.41% |
| 2021 | 18.12% |
| 2020 | 14.79% |
| 2019 | 1.72% |
| 2018 | -36.33% |
| 2017 | N/A |
Loading social stream, please wait...